Clinical Trials Browser

Phase 1/2 × Tetanus Toxoid × Tumor-Agnostic × Clear all

NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

80 enrolled 33 charts

Neoplasms